NIVOLUMAB-CONTAINING SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA MAY IMPAIR STEM CELL MOBILIZATION
Cytotherapy
· Elsevier
Abstract
Publication date: Available online 11 November 2026 Source: Cytotherapy Author(s): Maria K Angelopoulou, Athanasios Liaskas, Eleni Lalou, Aikaterini Benekou, Eleni Siavou, Alexandros Machairas, Aikaterini Kolotsiou, Eliana Konstantinou, Alexia Piperidou, Anastasia Kopsaftopoulou, Panagiotis T Diamantopoulos, Eleftheria Hatzimichael, Theodoros P Vassilakopoulos
Read at publisher →
Citation
NIVOLUMAB-CONTAINING SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA MAY IMPAIR STEM CELL MOBILIZATION. // Cytotherapy. – URL: https://www.sciencedirect.com/science/article/pii/S146532492601025X?dgcid=rss_sd_all
NIVOLUMAB-CONTAINING SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA MAY IMPAIR STEM CELL MOBILIZATION. Cytotherapy. https://www.sciencedirect.com/science/article/pii/S146532492601025X?dgcid=rss_sd_all
“NIVOLUMAB-CONTAINING SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA MAY IMPAIR STEM CELL MOBILIZATION.” Cytotherapy.
@article{article42991,
title = {NIVOLUMAB-CONTAINING SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA MAY IMPAIR STEM CELL MOBILIZATION},
journal = {Cytotherapy},
url = {https://www.sciencedirect.com/science/article/pii/S146532492601025X?dgcid=rss_sd_all}
}